Clinical trial
Abraxane and Temodar Plus Genasense in Advanced Melanoma
NCT00409383 · Genta Incorporated, Industry · Unknown status
Key facts
| NCT number | NCT00409383 |
|---|---|
| Title | Abraxane and Temodar Plus Genasense in Advanced Melanoma |
| Official title | A Pilot Study of Abraxane® (Albumin-bound Paclitaxel) and Temodar® (Temozolomide) Plus Genasense® (Oblimersen Sodium) in Subjects With Advanced Melanoma ("The ATG Study"). |
| Lead sponsor | Genta Incorporated, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Genasense® (oblimersen), Abraxane® (paclitaxel protein-bound particles for injectable suspension), Temodar® (temozolomide) |
| Enrollment | 28 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | Dec 8, 2006 |
| Last update posted | Nov 7, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: